Two Drug Interaction Studies of Sirolimus in Combination with Sorafenib or Sunitinib in Patients with Advanced Malignancies

PURPOSE: Sirolimus is the prototypical mammalian target of rapamycin inhibitor. Sorafenib and sunitinib are small molecule inhibitors of multiple kinases including vascular endothelial receptor kinases (VEGFR). These agents have different mechanisms of action providing a strong rationale for combina...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Gangadhar, Tara C., Cohen, Ezra E. W., Wu, Kehua, Janisch, Linda, Geary, David, Kocherginsky, Masha, House, Larry K., Ramirez, Jackie, Undevia, Samir D., Maitland, Michael L., Fleming, Gini F., Ratain, Mark J.
Format: Artigo
Jezik:Inglês
Izdano: 2011
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3077032/
https://ncbi.nlm.nih.gov/pubmed/21447721
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2061
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items